A new generation of radioactive drugs is heating up the lukewarm radiotherapeutics sector with isotopes that target diseased tissue without harming healthy cells.
Products in the pipeline appear potent at killing tumors while being unaffected by cellular resistance mechanisms. They have radioactive half-lives...